Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide

By Zheng Zhaohua   Aojula Harmesh   Clarke David  

Journal of Drug Targeting, Vol. 18, Iss. 6, 2010-07 ,pp. : 477-487

Informa Healthcare

Access to resources Recommend Favorite

Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquat

By Silva Renata   Sousa Emília   Carmo Helena   Palmeira Andreia   Barbosa Daniel   Gameiro Mariline   Pinto Madalena   Lourdes Bastos Maria   Remião Fernando  

Archives of Toxicology, Vol. 88, Iss. 4, 2014-04 ,pp. : 937-951

Springer Publishing Company

Access to resources Recommend Favorite

Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines

By van der Sandt I.C.J.   Blom-Roosemalen M.C.M.   de Boer A.G.   Breimer D.D.  

European Journal of Pharmaceutical Sciences, Vol. 11, Iss. 3, 2000-09 ,pp. : 207-214

Elsevier

Access to resources Recommend Favorite

The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells

By Brooks Tracy   O’Loughlin Kieran   Minderman Hans   Bundy Brian   Ford Laurie   Vredenburg Michael   Bernacki Ralph   Priebe Waldemar   Baer Maria  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 115-122

Springer Publishing Company

Access to resources Recommend Favorite

In silico Strategies to Probe Stereoselective Interactions of Multidrug Resistant Transporter P-glycoprotein

By  

Letters in Drug Design & Discovery, Vol. 13, Iss. 8, 2016-08 ,pp. : 824-832

Bentham Science Publishers

Access to resources Recommend Favorite